SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
After hours
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverBIIB
HealthcareNASDAQUSD

Biogen Inc.

$001234567890012345678900123456789.0012345678900123456789+6.8%
52w low (est.) $173.84$256.53 52w high (est.)
Peers
Market data
Market cap
$29.40B
52-week range
$121.05 – $219.72
Beta (vs market)
0.16
Sector
Healthcare
Valuation
P/E ratio
21.4x
DCF fair value
$358.05
Margin of safety
+71.4%
Forward P/E
12.0x
PEG ratio
4.20
Quality & efficiency
Moat score
61/100
Return on equity
7.7%
Profit margin
13.8%
Debt / equity
0.35
Growth & analysts
Revenue growth (YoY)
+1.9%
Analyst target
$222.83
Target upside
+6.7%
Analysts covering
31

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Valuation

ValueGrowthProfitHealthIncome46QUALITY
Overall Rating
68
Buy
Buy
Moat Score61
DCF Intrinsic Value
$358.05+71.4% upside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$29.40B
P/E Ratio
21.4
Dividend Yield
0.00%
Revenue Growth
+1.9%
Profit Margin
13.8%
ROE
7.7%
Debt / Equity
0.35
Beta
0.16
vs Healthcare sector:P/E 21 vs 28 · cheaperMoat 61 vs 7Yield 0.00% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · BIIB